Key Drivers
- Strong Liquidity
- High Margins
- Low Debt
AIAI Summary
KNSA is now a profitable, cash-generative specialty-pharma company, but at ~77x earnings and with ARCALYST driving nearly all value, investors should wait for sustained penetration-driven growth or a more attractive entry point while treating KPL-387 as upside optionality—not a proven second engine.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •High Margins
- •Low Debt
KNSA is financially strong with high margins, ample liquidity, low debt, and solid cash flow, but its elevated valuation and accumulated losses make the shares appear expensive.
Price Behavior
Key Price Behavior Insights:
- •Mild downtrend
- •Failed rebound
- •Key range
KNSA remains technically cautious after slipping last month and failing to hold its rebound, with support at $76.25–$76.50 and resistance at $79.33–$80.47.
Sharp rebound from $75.15 to $79.33 reversed quickly
Sentiment & News
Key News Insights:
- •Arcalyst sales
- •Pipeline progress
- •Investor outreach
Kiniksa's 41% rally reflects Arcalyst-driven momentum and pipeline optimism, reinforced by active investor engagement.
Positive commercial momentum and heightened visibility could support continued investor interest in KNSA
Similar Companies in Healthcare
Other companies in the same sector with AI ratings